ES2238001B1 - Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos. - Google Patents
Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos.Info
- Publication number
- ES2238001B1 ES2238001B1 ES200400115A ES200400115A ES2238001B1 ES 2238001 B1 ES2238001 B1 ES 2238001B1 ES 200400115 A ES200400115 A ES 200400115A ES 200400115 A ES200400115 A ES 200400115A ES 2238001 B1 ES2238001 B1 ES 2238001B1
- Authority
- ES
- Spain
- Prior art keywords
- ondansetron
- powder
- polymorphic form
- ray diffractogram
- form according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960005343 ondansetron Drugs 0.000 title claims abstract description 73
- 238000000034 method Methods 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 title abstract description 4
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims abstract description 72
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 206010047700 Vomiting Diseases 0.000 claims abstract description 7
- 238000011321 prophylaxis Methods 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 54
- 239000000843 powder Substances 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000000725 suspension Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 8
- 238000011084 recovery Methods 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 5
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 4
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 claims description 4
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 claims description 4
- 206010066963 Procedural vomiting Diseases 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000011393 cytotoxic chemotherapy Methods 0.000 claims description 4
- 230000008693 nausea Effects 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000012047 saturated solution Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 230000003474 anti-emetic effect Effects 0.000 abstract description 3
- 239000002111 antiemetic agent Substances 0.000 abstract description 3
- 229940125683 antiemetic agent Drugs 0.000 abstract description 2
- 238000002844 melting Methods 0.000 description 16
- 230000008018 melting Effects 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 238000001953 recrystallisation Methods 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 4
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 4
- 238000001237 Raman spectrum Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000000155 melt Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 238000001069 Raman spectroscopy Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- IOLDYYFAUYAFCO-BTJKTKAUSA-N (z)-but-2-enedioic acid;9-methyl-3-[(2-methylimidazol-1-yl)methyl]-1,2,3,4-tetrahydrocarbazole Chemical compound OC(=O)\C=C/C(O)=O.CC1=NC=CN1CC1CC(C=2C(=CC=CC=2)N2C)=C2CC1 IOLDYYFAUYAFCO-BTJKTKAUSA-N 0.000 description 1
- ZOHGNMNHFUUYCZ-UHFFFAOYSA-N 3-(chloromethyl)-9-methyl-2,3-dihydro-1h-carbazol-4-one Chemical compound C12=CC=CC=C2N(C)C2=C1C(=O)C(CCl)CC2 ZOHGNMNHFUUYCZ-UHFFFAOYSA-N 0.000 description 1
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical compound Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 description 1
- QMAAAVCBEQIZHZ-UHFFFAOYSA-N 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-1,2,3,4-tetrahydrocarbazol-4-ol Chemical compound CC1=NC=CN1CC1C(O)C(C=2C(=CC=CC=2)N2C)=C2CC1 QMAAAVCBEQIZHZ-UHFFFAOYSA-N 0.000 description 1
- AGQJDIDJKSFVTC-UHFFFAOYSA-N 9-methyl-3-methylidene-1,2-dihydrocarbazol-4-one Chemical compound C12=CC=CC=C2N(C)C2=C1C(=O)C(=C)CC2 AGQJDIDJKSFVTC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- -1 for example Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229960000770 ondansetron hydrochloride Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200400115A ES2238001B1 (es) | 2004-01-21 | 2004-01-21 | Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos. |
| PE2005000081A PE20050766A1 (es) | 2004-01-21 | 2005-01-20 | Nuevas formas polimorficas de ondasetron, procedimientos para su preparacion y composiciones farmaceuticas que los contienen |
| ARP050100194A AR047435A1 (es) | 2004-01-21 | 2005-01-20 | Variedades cristalinas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como antiemeticos |
| PCT/IB2005/000141 WO2005080381A1 (fr) | 2004-01-21 | 2005-01-20 | Nouvelles formes polymorphes d'ondansetron et leurs procedes de preparation, et compositions pharmaceutiques contenant lesdites nouvelles formes polymorphes et leur utilisation comme antivomitif |
| KR1020067014651A KR20060127892A (ko) | 2004-01-21 | 2005-01-20 | 온단세트론의 신규한 다형 형태, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 항구토제로서의 이의 용도 |
| JP2006550337A JP2007518791A (ja) | 2004-01-21 | 2005-01-20 | オンダンセトロンの新規多形体、該多形体の製造方法、該多形体を含有する医薬組成物、および抗嘔吐剤としての該多形体の使用 |
| EP05702302A EP1709033A1 (fr) | 2004-01-21 | 2005-01-20 | Nouvelles formes polymorphes d'ondansetron et leurs procedes de preparation, et compositions pharmaceutiques contenant lesdites nouvelles formes polymorphes et leur utilisation comme antivomitif |
| TW094101755A TW200528100A (en) | 2004-01-21 | 2005-01-21 | New polymorphic forms of ondansetron, processes for preparing them, pharmaceutical compositions containing them and their use as antiemetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200400115A ES2238001B1 (es) | 2004-01-21 | 2004-01-21 | Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2238001A1 ES2238001A1 (es) | 2005-08-01 |
| ES2238001B1 true ES2238001B1 (es) | 2006-11-01 |
Family
ID=34802828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200400115A Expired - Fee Related ES2238001B1 (es) | 2004-01-21 | 2004-01-21 | Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1709033A1 (fr) |
| JP (1) | JP2007518791A (fr) |
| KR (1) | KR20060127892A (fr) |
| AR (1) | AR047435A1 (fr) |
| ES (1) | ES2238001B1 (fr) |
| PE (1) | PE20050766A1 (fr) |
| TW (1) | TW200528100A (fr) |
| WO (1) | WO2005080381A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101331768B1 (ko) | 2005-11-08 | 2013-11-22 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제 |
| MX2009003372A (es) | 2006-10-02 | 2009-09-24 | Labtec Gmbh | Formas de dosificacion de pelicula no mucoadhesiva. |
| HRP20170241T2 (hr) | 2007-12-07 | 2023-03-17 | Vertex Pharmaceuticals Incorporated | Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline |
| EP2377526A1 (fr) | 2010-03-23 | 2011-10-19 | BioAlliance Pharma | Systèmes d'administration de médicaments à dissolution rapide |
| EP2549988A1 (fr) | 2010-03-23 | 2013-01-30 | Apr Applied Pharma Research S.A. | Systèmes d'administration de médicaments à dissolution rapide |
| DK3150198T3 (da) | 2010-04-07 | 2021-11-01 | Vertex Pharma | Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf |
| RU2718044C2 (ru) | 2013-11-12 | 2020-03-30 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003093260A1 (fr) * | 2002-04-30 | 2003-11-13 | Biogal Gyogyszergyar Rt. | Nouvelles formes cristallines d'ondansetron, procedes de preparation correspondant, compositions pharmaceutiques contenant ces nouvelles formes et procedes de traitement de la nausee au moyen des ces nouvelles formes |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU193592B (en) * | 1984-01-25 | 1987-11-30 | Glaxo Group Ltd | Process for producing tetrahydro-carbazolone derivatives |
| ES2199061B1 (es) | 2002-06-10 | 2005-02-16 | Laboratorios Vita, S.A. | Comprimidos bucodispersables y procedimiento para su obtencion. |
| FI6164U1 (fi) | 2003-01-09 | 2004-03-15 | Synthon Bv | Ondansetronmuotoja |
| DE20312772U1 (de) * | 2003-08-19 | 2003-10-30 | Synthon Bv | Ondansetron-Formen |
-
2004
- 2004-01-21 ES ES200400115A patent/ES2238001B1/es not_active Expired - Fee Related
-
2005
- 2005-01-20 WO PCT/IB2005/000141 patent/WO2005080381A1/fr not_active Ceased
- 2005-01-20 AR ARP050100194A patent/AR047435A1/es not_active Application Discontinuation
- 2005-01-20 JP JP2006550337A patent/JP2007518791A/ja not_active Withdrawn
- 2005-01-20 KR KR1020067014651A patent/KR20060127892A/ko not_active Withdrawn
- 2005-01-20 EP EP05702302A patent/EP1709033A1/fr not_active Withdrawn
- 2005-01-20 PE PE2005000081A patent/PE20050766A1/es not_active Application Discontinuation
- 2005-01-21 TW TW094101755A patent/TW200528100A/zh unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003093260A1 (fr) * | 2002-04-30 | 2003-11-13 | Biogal Gyogyszergyar Rt. | Nouvelles formes cristallines d'ondansetron, procedes de preparation correspondant, compositions pharmaceutiques contenant ces nouvelles formes et procedes de traitement de la nausee au moyen des ces nouvelles formes |
Non-Patent Citations (1)
| Title |
|---|
| MOOHI YOO KIM y col. An efficient process of Ondansetron sintesis. Heterocycles. 1997, Vol. 45, Nº 10, páginas 2041-2043, SIN 0385-5414. Página 2043, párrafo 1. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007518791A (ja) | 2007-07-12 |
| PE20050766A1 (es) | 2005-12-14 |
| WO2005080381A1 (fr) | 2005-09-01 |
| KR20060127892A (ko) | 2006-12-13 |
| AR047435A1 (es) | 2006-01-18 |
| ES2238001A1 (es) | 2005-08-01 |
| EP1709033A1 (fr) | 2006-10-11 |
| TW200528100A (en) | 2005-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI373470B (en) | Process for preparing amino crotonyl compounds | |
| CA3149900A1 (fr) | Composes inhibiteurs de rip1 et leurs procedes de fabrication et d'utilisation | |
| TWI845819B (zh) | 用作激酶抑制劑的化合物及其應用 | |
| ES2310410T3 (es) | Preparacion de risperidona. | |
| TW201000463A (en) | Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts | |
| CN112867717B (zh) | 用作激酶抑制剂的化合物及其应用 | |
| CA2022486C (fr) | 1,3-dihydro-1-(pyridinylamino)-2h-indol-2-ones, procede de preparation et utilisation en tant que medicaments | |
| TW200529838A (en) | Novel compounds | |
| ES2238001B1 (es) | Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos. | |
| JP2010536807A (ja) | キネシンスピンドルタンパク質（ｅｇ５）の阻害剤としてのインドロピリジン | |
| CN112321568B (zh) | 4-甲基吡咯取代的吲哚酮衍生物、其制备方法及其医药用途 | |
| JP4980431B2 (ja) | 抗ウイルス剤のマレイン酸モノ塩及びそれを含有する医薬組成物 | |
| WO2021110010A1 (fr) | Nouveau composé pyrrolique | |
| TW202404604A (zh) | [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式 | |
| CN111247153B (zh) | 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1，3]间二氧杂环戊烯并[4，5-f]吲哚-7-基)吡咯-2，5-二酮的固体形式 | |
| US8258168B2 (en) | 2H or 3H-benzo[E]indazol-1-YL carbamate derivatives, the preparation and therapeutic use thereof | |
| CN102653521B (zh) | 吲哚-2-酮的哌嗪硫代甲酰肼衍生物及其制备方法和用途 | |
| JP2860688B2 (ja) | インドール誘導体 | |
| ES2819286T3 (es) | Proceso para la producción a gran escala de oxalato de 1isopropil3{5[1(3metoxipropil) piperidin4il] [1,3,4]oxadiazol2il}1Hindazol | |
| RU2802964C2 (ru) | Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида | |
| CN110945001A (zh) | Fms样酪氨酸激酶抑制剂 | |
| ES2357885T3 (es) | FORMAS POLIMORFAS DE N-(2,3-DIMETIL-5,6,7,8-TETRAHIDROFURO[2,3-b]QUINOLÍN-4-IL)-2-(2-OXOPIRROLIDÍN-1-IL)ACETAMIDA. | |
| JP4328873B2 (ja) | 放射線増感剤 | |
| JP2004525985A (ja) | Ｎ−（２，３−ジメチル−５，６，７，８−テトラヒドロフロ［２，３−ｂ］キノリン−４−イル）−２−（２−オキソプロリジン−１−イル）アセトアミドの結晶多形 | |
| WO2025247067A1 (fr) | Inhibiteur de kif18a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20050801 Kind code of ref document: A1 |
|
| FG2A | Definitive protection |
Ref document number: 2238001B1 Country of ref document: ES |
|
| PC2A | Transfer of patent |
Owner name: WARNER CHILCOTT IBERIA, S.L. Effective date: 20120411 |
|
| PC2A | Transfer of patent |
Owner name: LABORATORIOS LESVI, S.L. Effective date: 20120917 |
|
| PC2A | Transfer of patent |
Owner name: INKE S.A. Effective date: 20190227 |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20240126 |